162 related articles for article (PubMed ID: 28238899)
1. Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.
Kudo T; Goda H; Yokosuka Y; Tanaka R; Komatsu S; Ito K
J Pharm Sci; 2017 Sep; 106(9):2847-2852. PubMed ID: 28238899
[TBL] [Abstract][Full Text] [Related]
2. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
4. Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes.
Kudo T; Ozaki Y; Kusano T; Hotta E; Oya Y; Komatsu S; Goda H; Ito K
Xenobiotica; 2016; 46(3):241-6. PubMed ID: 26290405
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.
Säll C; Houston JB; Galetin A
Drug Metab Dispos; 2012 Jul; 40(7):1279-89. PubMed ID: 22451699
[TBL] [Abstract][Full Text] [Related]
6. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
[TBL] [Abstract][Full Text] [Related]
7. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
Kim SJ; Toshimoto K; Yao Y; Yoshikado T; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2715-2726. PubMed ID: 28479356
[TBL] [Abstract][Full Text] [Related]
9. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
[TBL] [Abstract][Full Text] [Related]
13. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
15. Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications.
Heinig R; Gerisch M; Bairlein M; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):433-444. PubMed ID: 32125665
[TBL] [Abstract][Full Text] [Related]
16. CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats.
Xu Y; Zhou D; Wang Y; Li J; Wang M; Lu J; Zhang H
Food Chem Toxicol; 2016 Aug; 94():138-47. PubMed ID: 27259818
[TBL] [Abstract][Full Text] [Related]
17. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
Wang Y; Wang M; Qi H; Pan P; Hou T; Li J; He G; Zhang H
Drug Metab Dispos; 2014 Apr; 42(4):782-95. PubMed ID: 24476576
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
19. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2011 May; 39(5):904-11. PubMed ID: 21289076
[TBL] [Abstract][Full Text] [Related]
20. Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.
Giri P; Delvadia P; Ladani MK; Prajapati N; Gupta L; Patel N; Joshi V; Giri S; Jain MR; Srinivas NR; Patel PR
Eur J Pharm Sci; 2019 Mar; 130():107-113. PubMed ID: 30633968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
